LAFM Summit on November 19-21, 2025 in Boston, United States

Biopharma R AND D currently faces a weaker funding period and fluctuating headcounts all while scientific operations and investments continue - seen as Wuxi and Johnson and Johnson expand their R AND D collaboration and Roche expands its research capabilities. As the backbone of scientific support, asset managers, facilities, and procurement professionals must embrace more intelligent utilization of lab operations systems and promote their vital shift towards complete digitization.

The 8th Lab Asset and Facility Management Summit (LAFM) is returning to unite 200+ senior lab operations, facilities, asset and procurement professionals across biopharma, CDMOs, CROs, and diagnostics, to live and breathe lean operations as a non-negotiable in the lab environment and supporting complete integration of all facets of operations within budget.

URLs:

Tickets: https://go.evvnt.com/3167703-2?pid=10008

Brochure: https://go.evvnt.com/3167703-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developers, CDMO, CRO and Diagnostics Pricing - Conference Only: USD 2399.00,

Drug Developers, CDMO, CRO and Diagnostics Pricing - Conference + Workshop Day: USD 3197.00,

Not-for-Profits, Academics and Start-up Pricing - Conference Only: USD 1999.00,

Not-for-Profits, Academics and Start-up Pricing - Conference + Workshop Day: USD 2697.00,

Solution Provider Pricing - Conference Only: USD 3699.00,

Solution Provider Pricing - Conference + Workshop Day: USD 5097.00

Speakers: Andrew Cournoyer Associate Director, Workplace Services Vertex Pharmaceuticals, Angela Paradiso Director, Lab Operations Emulate, Anthony Cammarano Lab Operations Manager City Therapeutics, Anthony Michetti Director, Sustainability Cell Signalling Technology, Asiem Bhaskar Senior Manager, Laboratory and Facilities Services Arbor Biotechnologies, Avery Zartarian Senior Associate, Lab Operations Be Biopharma, Bailey Keown Senior Manager, Lab Operations Archon Bio, Barton Nielsen Associate Director, Facilities Solid Biosciences, Brandon King Director, Operations Sanofi, Bridget Byrne Senior Manager, Lab Operations Accent Therapeutics, Caroline Durkin Head, Cambridge Operations AstraZeneca, Christine Lavery Head, Global Scientific Services GlaxoSmithKline, Christopher Toomey Senior Manager, Lab Operations Enanta Pharmaceuticals, Ciara Selders Lab Operations Manager Novartis, Claire Stingley Director, Lab and Facilities Operations Ensoma, Grace Rosario Director, Safety, Health and Environment AstraZeneca, Igor Deyneko Laboratory Operations Manager Novartis, Jessica Hilton Senior Director Pfizer, Jonathan Abdala Associate Director, EHS Athos Therapeutics, Joseph Twomey Associate Director, Laboratory Equipment Operations Novartis, Judith Janette Associate Director, Lab Operations Immunai, Karilyn Ullrich Head, Research Lab Operations, US GlaxoSmithKline, Keith Anderson Senior Manager, Lab Operations Cell Signaling Technology, Keli Rodriguez Associate Director, Facilities and Lab Ops EpiCypher, Lady Perez Senior Specialist, Facilities Operations Vertex Pharmaceuticals, Lisa Freimark Laboratory Operations Manager Terrana Biosciences, Liz Fuller Facilities Operations Manager Vertex Pharmaceuticals, Liz Kentish MD Kentish and Co, Luciano Ranallo Associate Director, Facilities Operations Regeneron Pharmaceuticals, Michael Nichols Director, Facilities Ultragenyx, Michael Notkin Laboratory Operations Manager Corner Therapeutics, Peggy Weber Director, Laboratory Systems Sarepta Therapeutics, Radia Wahab Director, Systems Integration and Engineering Guardant Health, Rebecca Servais Director, Facility Operations Dyno Therapeutics, Ronald Amoling Associate Director EHS Bristol Myers Squibb, Rose McCarthy Senior Director, Site Operations, Boston R AND D AstraZeneca, Sam Cooper Senior Director, Facilities Operations Regeneron Pharmaceuticals, Sam Wang Senior Lab Manager Sonoma Biotherapeutics, Thanmayi Ranganath Associate Director, R AND D Operations Sonoma Biotherapeutics, Toni Russo Director, Facilities Acadia Pharmaceuticals